Chemours Q2 2026 Earnings: TiO2 Price Tilts, But EPS Isn’t (Yet) Righted

Overview: revenue strength from price, but GAAP EPS still in the red

Chemours, ticker CC, reported second-quarter 2026 results that read like a tug‑of‑war between top‑line momentum and the inertia of costs. Net Sales came in at about $1.6 billion, a level that sits roughly flat versus the prior year on a pricing‑driven mix across businesses. The company posted a net loss attributable to Chemours of $274 million, or $1.81 per diluted share, compared with a $380 million loss, or $2.53 per diluted share, in the corresponding prior‑year quarter. In non‑GAAP terms, Adjusted Net Income was $64 million, or $0.42 per diluted share, versus $91 million, or $0.61 per diluted share, a year ago.

Note the distinction between GAAP EPS and Adjusted EPS. The headline numbers show a deteriorating GAAP bottom line, while the company frames ongoing profitability through adjusted metrics. As always, investors will want to compare these figures to their EPS consensus and watch for any earnings surprise—if the market had priced in a sunnier quarter, that gap may have mattered for near‑term momentum.

Financial Highlights

• Net Sales: $1.6 billion, broadly flat year over year as pricing offsets volume dynamics across segments.
• GAAP EPS: -$1.81 per diluted share, reflecting the quarterly loss on a higher absolute cost structure or non‑recurring items; prior year was -$2.53.
• Adjusted EPS: $0.42 per diluted share, down from $0.61 in the prior year; management highlights ongoing discipline in the cost base and favorable product mix.
• Adjusted EBITDA: approximately $247 million, slightly softer than the prior‑year quarter’s $260 million, with some drag from the year‑over‑year comparison in TSS aftermarket performance.
• Free Cash Flow: improved 128% year over year, with a 46% Free Cash Flow Conversion and net leverage at 4.4x; Chemours continues to target leverage below 3x over the long run.
• Capital Allocation Signal: announced an additional global TiO2 price increase effective June 1, 2026, contributing to a roughly 5% year‑to‑date TiO2 price lift in Net Sales.
• Segment Highlights: APM Performance Solutions Net Sales grew about 8% year over year, underscoring momentum in higher‑value specialty products serving data center and semiconductor markets.

What this implies for Chemours and peers

The quarter reads as a tale of two economies inside one company: price recovery and mix benefit bolting against a backdrop of lower or less predictable earnings leverage. The TiO2 price increases are a deliberate step toward preserving margin in a commodity‑heavy segment, but they don’t magically reprice the durable‑goods demand cycle or eliminate the costs that haunted GAAP earnings this quarter. Investors will want to watch how durable the price uplift proves across the year and whether demand for APM’s data‑center and semiconductor solutions can sustain the 8% top‑line growth as clients recalibrate capex cycles.

From a sector viewpoint, the combination of a leverage profile at 4.4x and a stated target to hold leverage below 3x signals a deliberate tightening in financial policy. If the company can sustain free cash flow generation while slowly accruing leverage relief, it may provide a blueprint for other chemical players contending with variable TiO2 and specialty product cycles. In the near term, the market will likely respond to any signs that the revenue forecast for TiO2 price lift is not fully baked into sell‑side expectations, or that the Adjusted EBITDA trajectory improves as the price increases wind into higher volumes from the product mix shift.

As for peers, the message is mixed: price signals matter, but the delta between GAAP losses and adjusted profitability remains a crucible for investor sentiment. The industry’s appetite for capital efficiency, price discipline, and the pace of demand normalization in end markets (notably coatings, performance materials, and electronics) will set the tone for the sector’s multiple–capability narrative in the second half of 2026.

Bottom line and takeaways

Chemours’ Q2 narrative is not a reset, but a re‑calibration. The stronger cash performance and the price actions in TiO2 point to management’s focus on margin preservation in a fluctuating pricing environment. Yet the GAAP EPS line remains negative, and investors will be watching whether the EPS consensus for 2026 earnings moves meaningfully higher as the year progresses. The stock’s fate may hinge on whether better cash conversion translates into leverage relief and whether the TiO2 price trajectory can be sustained without eroding demand elasticity.

For investors betting on CC and the broader specialty chemicals space, the key questions are: will the revenue forecast in more durable segments hold up as end markets cool or reaccelerate, and can the company meaningfully expand Adjusted EBITDA and Free Cash Flow to converge toward the long‑term leverage target? If the answers tilt in the affirmative, Chemours may emerge as a test case for how a cyclical, commodity‑exposed business can navigate inflationary cost pressures while still delivering shareholder value through capital discipline.